Eli Lilly stated "Lilly is deeply concerned that products fraudulently claimed by compounding pharmacies or counterfeiters to be FDA-approved tirzepatide, Mounjaro, or Zepbound may expose patients to serious health risks." Novo Nordisk said its lawsuits "aim to protect US patients and consumers from deceptive marketing by these entities as well as potentially harmful and improperly compounded drugs claiming to contain semaglutide." At least seven deaths linked to compounded versions of semaglutide, the active ingredient in these medications, have been reported to the FDA
N.MakogonN
[DOI] [PubMed] [Google Scholar] 171.Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al
October 3, 2025- As of October 3, 2025, there are over 2,809 lawsuits in the MDL pertaining to Ozempic, Mounjaro and numerous other GLP-1 medications
MOAA is urging the Defense Health Agency and lawmakers to halt plans that would end coverage of GLP-1 weight loss drugs for TRICARE For Life (TFL) beneficiaries in the coming days plans which risk the progress made by patients taking these medications and cast doubt on the future of the TFL benefit
